Call Us Today for a FREE CONSULTATION 205-933-1500
Jan 09 2012

Excedrin, NoDoz, Bufferin And Gas-X Recalled; Bottles May Contain Other Pills

Posted in Community Service, Product Liability

The mixing of  drug products during the manufacturing and bottling process may cause medical issues to the unaware consumer, says Alabama liability attorney Keith T. Belt

Novartis Consumer Health, Inc. has announced a voluntarily recall of all lots of select bottle packaging configurations of Excedrin and NoDoz products with expiration dates of Dec. 20, 2014 or earlier, as well as Bufferin and Gas-X Prevention products with expiration dates of Dec. 20, 2013 or earlier. According to an FDA press release, the products may contain stray tablets, capsules, or caplets from other Novartis products, or contain broken or chipped tablets.

The list of affected bottles are:

All lots of Bufferin® products with expiry dates of December 20, 2013 or earlier.

Bufferin® Extra Strength Tablets

Bufferin® Low Dose Tablets

Bufferin® Regular Strength Tablets

All lots of the following Excedrin® products have been recalled with expiry dates of December 20, 2014 or earlier

Excedrin® Extra Strength Caplets

Excedrin® Extra Strength Express Gel Caplets

Excedrin® Extra Strength Gel Caplets

Excedrin® Extra Strength Tablets

Excedrin® Back & Body Caplets

Excedrin® Sinus Headache Caplets

Excedrin® Migraine Caplets

Excedrin® Migraine Gel Tablets

Excedrin® Migraine Tablets

Excedrin® Menstrual Complete Express Gel Caplets

Excedrin® PM Caplets

Excedrin® PM Express Gel Caplets

Excedrin® PM Tablets

Excedrin® Tension Headache Caplets

Excedrin® Tension Headache Express Gel Caplets

Excedrin® Tension Headache Gel Tablets

All lots of Gas-X® Prevention® products with expiry dates of December 20, 2013 or earlier.

All lots of NoDoz® products with expiry dates of December 20, 2014 or earlier

According to the FDA release, “mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended or receiving an unintended ingredient. This could potentially result in overdose, interaction with other medications a consumer may be taking, or an allergic reaction if the consumer is allergic to the unintended ingredient.”

The release goes on to say consumers that have the product(s) being recalled should stop using the product(s) and contact the Novartis Consumer Relationship Center at 1-888-477-2403 (available Monday-Friday 8 a.m. to 7 p.m. Central Time) for information on how to return the affected products and receive a full refund. For more detailed information, consumers should visit the Norvartis website at http://www.novartis-otc.com/otc/index.html Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these drug products.